'

DFNS.net CBRN News Blog

0

Ebola Survivor Treated with Hemopurifier Therapy

Aethlon Medical, Inc. announced this week that officials at Frankfurt University Hospital have reported no detectable virus in an Ebola patient previously disclosed to have received Hemopurifier therapy with Aethlon’s novel bio-purification device. The...

0

Japan and North Korea’s kidnap negotiations stall

Key Points Japan appears committed to tempering its hardline posture towards North Korea despite Pyongyang’s belligerence, with the issue of Japanese abductees in North Korea assuming greater importance in bilateral relations. Despite this, Japanese...

0

European nations seek common MCM toolkit

Key Points Six European nations are conducting a three-year study to establish requirements for modular systems to counter mine threats The Maritime Mine Counter Measures – New Generation (MMCM-NG) research project could also help...

0

Wearable Early Warning for Chem-Bio Threats

The Defense Threat Reduction Agency (DTRA) is interested in proposals for wearable sensor technologies to provide an early warning capability for chemical and biological threat exposure. The ideal deployable system would be a very...

0

Paper-Based Devices for Far-Forward Multiplex Diagnostics

The Defense Threat Reduction Agency (DTRA) is interested in proposals for applied research to characterize and analyze the critical properties of vertical flow proteomic paper substrates for use in Point of Need (PON) far-forward...

0

Ebola scare sparks Parliament lockdown

THE NEW ZEALAND HERALD – Parliament was hit with an Ebola scare late this afternoon just hours after a similar incident at the Herald’s head office in Auckland. A police spokesman this afternoon confirmed...

0

Russia to build Iran nuclear reactors

ALJAZEERA – Russia has signed a contract to build two more nuclear reactors in Iran likely to be followed with another six, a move intended to cement closer ties between the two nations. The...

0

Second Ebola Vaccine Trial in Switzerland

GLOBAL BIODEFENSE – Swissmedic, the Swiss regulatory authority for therapeutic products, has approved a second Swiss trial of an experimental Ebola vaccine. The trial will be led by the University Hospitals of Geneva (HUG)....

0

Libyan Town in the Hands of IS?

By Erik Goepner In early October, the Islamic Youth Shura Council announced that Darnah, Libya, had joined the Islamic State’s caliphate. Alternatively referred to as Derna or Darna, 80,000 call the city home. Sitting...

0

Down the slippery slope

The Universities of Bradford and Bath have produced a joint report highlighting how contemporary chemical and life science research may potentially be applied to the study or creation of incapacitating chemical agent weapons. …read...

0

Bomb at School in Nigeria Kills Nearly 50 Boys

THE NEW YORK TIMES – A suicide attacker disguised as a student detonated a bomb at a boarding school in northern Nigeria on Monday morning, killing nearly 50 boys who were between 10 and...

0

Arco chosen to supply ebola PPE

Arco meet UK government’s urgent operational requirement for Ebola PPE sets and PPE advice …read more From:: CBRNe World (CBRN)

0

Russian troops get new wheels

Russian special forces NBC defence troops get new detector vehicles …read more From:: CBRNe World (CBRN)

0

Bruker De-tector passes ECAC

The Bruker Detection division today announced that the DE-tector has successfully met the new European Civil Aviation Conference’s (ECAC) Common Evaluation Process of Security Equipment (CEP) for airport checkpoint screening of passengers and baggage...

0

3M’s M61 ordered by US Army

The U.S. Army has placed its first order for the new 3M M61 Respiratory Mask Canister through the Canadian Commercial Corporation …read more From:: CBRNe World (CBRN)

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close